A new initiative announced by the National Institutes of Health (HNIH), backed by a $1.5 billion investment from federal stimulus funding, aims to speed innovation, development, and commercialization of COVID-19 testing technologies. Dubbed the Rapid Acceleration of Diagnostics (RADx) initiative the new program will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing.
TEDOR Pharma LicensesFLEXITABTMBreakable Extended ReleaseTabletTechnology
Patent protected FLEXITAB technology delivers flexible and precise dosing from a single extended release tablet CUMBERLAND, RI – May [31], 2019 – TEDOR Pharma Inc., a Contract Development and Manufacturing Organization with an 18-year operating history, is pleased to...